GLP-1 therapy may be appropriate for adults with: Treatment decisions should always be individualized after reviewing medical history, laboratory data, current medications, and overall health goals
Their primary concern is blood sugar destabilization
Novo Nordisk filed the New Drug Application (NDA) for CagriSema in early 2026, based on positive results from the REDEFINE phase 3 trial program
How to Start GLP-1 Treatment Without Insurance: The PlexusDx Process Accessing GLP-1 medication through PlexusDx requires no insurance verification, membership enrollment, or prior authorization delays
Given the significant prevalence of obesity among individuals with diabetes, these medications provide a comprehensive approach towards managing both conditions simultaneously
For this reason, some GLP-1 manufacturers recommend using non-oral contraception for four weeks after starting or increasing tirzepatide to reduce the risk of unintended pregnancy